Starpharma Holdings Limited has received an AU$ 5.5 million R&D Tax Incentive refund

Starpharma Holdings Limited (ASX: SPL) announces the receipt of a significant AU$5.5 million Research and Development (R&D) Tax Incentive refund for the 2024 financial year. This refund results from eligible R&D activities across Starpharma's portfolio, including the company's pioneering DEP drug delivery programs and VIRALEZE.

Through the Australian Government's R&D Tax Incentive program, Starpharma and similar companies receive a refundable tax offset for their impactful R&D initiatives. This strategic initiative is designed to stimulate investment in R&D, driving innovation and ultimately enhancing Australia's global competitiveness while catalyzing economic growth and generating new job opportunities.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com